Piper Sandler Raises Madrigal Pharmaceuticals (NASDAQ:MDGL)

Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) had its price objective hoisted by equities researchers at Piper Sandler from $305.00 to $336.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s price target suggests a potential upside of 45.91% […]

Related Keywords

United States , Piper Sandler , Roberte Waltermire , Osaic Holdings Inc , News Ratings For Madrigal Pharmaceuticals Daily , Exchange Traded Concepts , Montaga Associates Inc , Securities Exchange Commission , Russell Investments Group Ltd , Madrigal Pharmaceuticals , Analyst Recommendations For Madrigal Pharmaceuticals , Institutional Investors Weigh In On Madrigal Pharmaceuticals , Madrigal Pharmaceuticals Inc , Madrigal Pharmaceuticals Company Profile , Madrigal Pharmaceuticals Price Performance , Global Retirement Partners , Get Free Report , Advisors Lp Baker , Exchange Commission , Retirement Partners , Traded Concepts , Investments Group , Osaic Holdings , Madrigal Pharmaceuticals Daily , Nasdaq Mdgl , Mdgl , Medical , 87162t20 , Boost Price Target ,